D Galasko

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Biomarkers for Alzheimer's disease--clinical needs and application
    Douglas Galasko
    Department of Neurosciences, University of California, San Diego, Veterans Affairs Medical Center, CA 92161, USA
    J Alzheimers Dis 8:339-46. 2005
  2. ncbi Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition
    Elaine R Peskind
    VA Puget Sound Health Care System, Mental Illness Research, Education, and Clinical Center, Seattle, WA 98108, USA
    Arch Neurol 63:936-9. 2006
  3. ncbi ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials
    Douglas Galasko
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093 0624, USA
    Alzheimer Dis Assoc Disord 20:S152-69. 2006
  4. ncbi Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia
    Purnima Desai Sundar
    Department of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA 98195, USA
    Hum Mol Genet 16:295-306. 2007
  5. ncbi Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE
    D Galasko
    Department of Neurosciences, University of California, San Diego, CA, USA
    Neurology 68:1772-81. 2007
  6. pmc Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures
    Douglas R Galasko
    Department of Neurosciences, University of California, San Diego, 92093, USA
    Arch Neurol 69:836-41. 2012
  7. ncbi Lewy bodies and dementia
    D Galasko
    Department of Neurology, Veterans Affairs Medical Center, 127, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    Curr Neurol Neurosci Rep 1:435-41. 2001
  8. ncbi Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease
    D Galasko
    Department of Neurology, V127, University of California, San Diego, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    J Int Neuropsychol Soc 11:446-53. 2005
  9. ncbi Biological markers and the treatment of Alzheimer's disease
    D Galasko
    Department of Neurosciences, University of California, San Diego, USA
    J Mol Neurosci 17:119-25. 2001
  10. ncbi Clinical features and changing patterns of neurodegenerative disorders on Guam, 1997-2000
    D Galasko
    Department of Neurosciences, University of California, San Diego, USA
    Neurology 58:90-7. 2002

Research Grants

  1. AGE RELATED NEURODEGENERATIVE DISEASES IN MICRONESIA
    Douglas Galasko; Fiscal Year: 2006
  2. Biomarkers in Aging, MCI and Alzheimer's Disease
    Douglas Galasko; Fiscal Year: 2007

Detail Information

Publications56

  1. ncbi Biomarkers for Alzheimer's disease--clinical needs and application
    Douglas Galasko
    Department of Neurosciences, University of California, San Diego, Veterans Affairs Medical Center, CA 92161, USA
    J Alzheimers Dis 8:339-46. 2005
    ..As efforts to diagnose and treat AD move towards earlier intervention and even towards prevention, biomarkers will gain significance as tools to aid research and ultimately clinical practice...
  2. ncbi Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition
    Elaine R Peskind
    VA Puget Sound Health Care System, Mental Illness Research, Education, and Clinical Center, Seattle, WA 98108, USA
    Arch Neurol 63:936-9. 2006
    ..Normal aging and the presence of the apolipoprotein E (APOE*4) allele are the most important known risk factors for Alzheimer disease...
  3. ncbi ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials
    Douglas Galasko
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093 0624, USA
    Alzheimer Dis Assoc Disord 20:S152-69. 2006
    ..ADL change during a trial could trigger detailed evaluation or serve as an outcome measure. A brief, easily administered, and reliable ADL rating scale would assist prevention studies...
  4. ncbi Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia
    Purnima Desai Sundar
    Department of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA 98195, USA
    Hum Mol Genet 16:295-306. 2007
    ..Others have shown that SNP6 is also associated with risk for progressive supranuclear palsy. These two independent cis-acting sites presumably influence risk for Guam neuro-degenerative disorders by regulating MAPT expression...
  5. ncbi Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE
    D Galasko
    Department of Neurosciences, University of California, San Diego, CA, USA
    Neurology 68:1772-81. 2007
    ..To estimate the prevalence of dementia and its clinical subtypes among Chamorros on Guam aged 65 years or older and to examine associations with age, gender, education, and APOE genotype...
  6. pmc Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures
    Douglas R Galasko
    Department of Neurosciences, University of California, San Diego, 92093, USA
    Arch Neurol 69:836-41. 2012
    ..To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers...
  7. ncbi Lewy bodies and dementia
    D Galasko
    Department of Neurology, Veterans Affairs Medical Center, 127, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    Curr Neurol Neurosci Rep 1:435-41. 2001
    ..Pharmacologic management of cognitive and behavioral symptoms in patients with DLB is being explored. There is evidence that cholinesterase inhibitors may have beneficial effects...
  8. ncbi Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease
    D Galasko
    Department of Neurology, V127, University of California, San Diego, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    J Int Neuropsychol Soc 11:446-53. 2005
    ..Detailed evaluation of ADL may provide a useful index to evaluate patients with moderate to severe AD and may complement cognitive assessment, especially for characterizing change in interventional or therapeutic studies...
  9. ncbi Biological markers and the treatment of Alzheimer's disease
    D Galasko
    Department of Neurosciences, University of California, San Diego, USA
    J Mol Neurosci 17:119-25. 2001
    ..In large-scale clinical trials or in clinical practice, biomarkers that are easy to access, such as blood or urine tests, could help in evaluating effects of treatment...
  10. ncbi Clinical features and changing patterns of neurodegenerative disorders on Guam, 1997-2000
    D Galasko
    Department of Neurosciences, University of California, San Diego, USA
    Neurology 58:90-7. 2002
    ..Although ALS and PDC were reported to have dramatically declined in the 1980s, new cases are still encountered. Late-life dementia has received little study among Chamorros...
  11. ncbi Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals
    Douglas R Galasko
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA
    Alzheimer Dis Assoc Disord 21:292-9. 2007
    ..The safety, tolerability, and pharmacokinetic profile of R-flurbiprofen in these older individuals support the ongoing studies of this compound in patients with Alzheimer disease...
  12. ncbi New approaches to diagnose and treat Alzheimer's disease: a glimpse of the future
    D Galasko
    Department of Neurosciences, University of California, San Diego, California 92161, USA
    Clin Geriatr Med 17:393-410. 2001
    ..Therefore, this article highlights findings concerning biological markers for Alzheimer's disease and the mild cognitive impairment syndrome and attempts to define a prodromal stage of Alzheimer's disease...
  13. ncbi Measuring cognitive change in a cohort of patients with Alzheimer's disease
    D R Galasko
    Department of Neurosciences, University of California, San Diego, 3350 La Jolla Village Drive, V127 San Diego, CA 92161, USA
    Stat Med 19:1421-32. 2000
    ..The metric properties and longitudinal characteristics of cognitive tests and the statistical methods used to calculate change are key factors in obtaining reliable estimates of change in studying cohorts of patients with AD...
  14. pmc Biomarkers of oxidative damage and inflammation in Alzheimer's disease
    Douglas Galasko
    Department of Neurosciences, UCSD, La Jolla, CA 92093, USA
    Biomark Med 4:27-36. 2010
    ....
  15. ncbi Abeta1-42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD
    E Masliah
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093 0624, USA emasliah ucsd edu
    Neurology 61:206-11. 2003
    ....
  16. ncbi Cholinergic deficits in the brains of patients with parkinsonism-dementia complex of Guam
    E Masliah
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093-0624, USA
    Neuroreport 12:3901-3. 2001
    ..This deficit was similar to that seen in Alzheimer's disease and less severe than Lewy body disease. Thus, cholinergic deficits in the neocortex might contribute to some of the cognitive alterations in PDC of Guam...
  17. ncbi Rate of progression differs in frontotemporal dementia and Alzheimer disease
    K Rascovsky
    University of California, San Diego, La Jolla, CA 92093 0948, USA
    Neurology 65:397-403. 2005
    ..To compare survival and rates of cognitive and functional decline in patients with autopsy-confirmed frontotemporal dementia (FTD) and Alzheimer disease (AD) in a large multicenter study...
  18. ncbi Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies
    A R Merdes
    Department of Neurosciences, University of California, San Diego 92161, USA
    Neurology 60:1586-90. 2003
    ..To determine whether AD neurofibrillary pathology influences clinical diagnostic accuracy in dementia with Lewy bodies (DLB)...
  19. ncbi Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease
    C M Clark
    Department of Neurology, Alzheimer s Disease Center, University of Pennsylvania, Philadelphia 19104, USA
    Arch Neurol 56:857-62. 1999
    ..To determine the variability in annual Mini-Mental State Examination scores of patients with Alzheimer disease enrolled in the Consortium to Establish a Registry for Alzheimer's Disease (CERAD)...
  20. ncbi Cognitive profiles differ in autopsy-confirmed frontotemporal dementia and AD
    K Rascovsky
    Department of Neurosciences, University of California at San Diego, La Jolla 92093 0948, USA
    Neurology 58:1801-8. 2002
    ..Therefore, a retrospective examination of neuropsychological test performance in autopsy-confirmed patients is warranted...
  21. pmc Distinct cognitive profiles and rates of decline on the Mattis Dementia Rating Scale in autopsy-confirmed frontotemporal dementia and Alzheimer's disease
    Katya Rascovsky
    Memory and Aging Center, University of California, San Francisco, California, USA
    J Int Neuropsychol Soc 14:373-83. 2008
    ..8 points/year) on MDRS total and specific subscale scores. These results suggest that the MDRS may be a useful adjunct to other clinical measures for distinguishing FTD from AD and tracking the progression of the disorder...
  22. ncbi ALS and PDC of Guam: forty-year follow-up
    C C Plato
    Department of Neurosciences, University of California San Diego School of Medicine, La Jolla 92093 0624, USA
    Neurology 58:765-73. 2002
    ..Patients and individually matched controls and their relatives were registered from 1958 to 1963. The registry was updated and analyzed in 1998 through 1999...
  23. ncbi Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease
    M W Bondi
    San Diego Veterans Affairs Medical Center and Department of Psychiatry and School of Medicine, University of California, 92161, USA
    Psychol Aging 14:295-303. 1999
    ..Results support the importance of specific episodic memory changes and possession of the ApoE-epsilon4 allele in the preclinical detection of AD...
  24. ncbi Rate of cognitive change in Alzheimer's disease: methodological approaches using random effects models
    R Gould
    Department of Statistics, University of California, Los Angeles 90095 1554, USA
    J Int Neuropsychol Soc 7:813-24. 2001
    ..We discuss modeling these longitudinal data, and discuss use of the estimates of rate of change and intercept as data in their own right...
  25. ncbi Disparate letter and semantic category fluency deficits in autopsy-confirmed frontotemporal dementia and Alzheimer's disease
    Katya Rascovsky
    Department of Neurosciences, University of California, San Diego, CA, USA
    Neuropsychology 21:20-30. 2007
    ..These unique patterns of letter and semantic category fluency deficits may be indicative of differences in the relative contribution of frontal-lobe-mediated retrieval deficits and temporal-lobe-mediated semantic deficits in FTD and AD...
  26. ncbi Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study
    W Samuel
    Department of Neurosciences, University of California, San Diego, La Jolla, 92093 0624, USA
    Int J Geriatr Psychiatry 15:794-802. 2000
    ..For all subjects, an increase in MMSE scores across 6 months of treatment correlated with a decline in BEHAVE-AD scores...
  27. pmc Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
    Am J Geriatr Psychiatry 16:469-77. 2008
    ....
  28. pmc The role of biomarkers in clinical trials for Alzheimer disease
    Leon J Thal
    University of California San Diego, Department of Neurosciences, La Jolla, California, USA
    Alzheimer Dis Assoc Disord 20:6-15. 2006
    ..Additionally, biochemical biomarkers in blood or cerebrospinal fluid are assessed. Currently appropriate uses of biomarkers in the study of Alzheimer disease, and areas where additional work is needed, are discussed...
  29. ncbi Extrapyramidal motor signs in clinically diagnosed Alzheimer disease
    R J Ellis
    Department of Neurosciences, University of California, San Diego, USA
    Alzheimer Dis Assoc Disord 10:103-14. 1996
    ..Investigators should report frequencies for individual parkinsonian signs in addition to the overall prevalence of EPS to facilitate meaningful comparisons across studies...
  30. ncbi Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer's disease
    Laura Mickes
    Department of Psychology, University of California, San Diego, CA 92093 0109, USA
    Neuropsychology 21:696-705. 2007
    ....
  31. pmc Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies
    Joanne M Hamilton
    Department of Neurosciences, University of California, USA
    Neuropsychology 22:729-37. 2008
    ....
  32. pmc Comparison of the memory performance index with standard neuropsychological measures of cognition
    Michael Rafii
    Shiley Marcos Alzheimer s Disease Research Center and the Department of Neurosciences, University of California, San Diego, CA, USA
    Am J Alzheimers Dis Other Demen 26:235-9. 2011
    ..The MCIS may be a valuable tool in the identification of elderly at high risk for dementia due to its ease-of-use and brief administration time...
  33. pmc The effects of prolonged stress and APOE genotype on memory and cortisol in older adults
    Guerry M Peavy
    Department of Neurosciences, University of California, San Diego, California, USA
    Biol Psychiatry 62:472-8. 2007
    ..Combined effects of stress and APOE status on memory and cortisol in humans have not been studied...
  34. pmc Effects of chronic stress on memory decline in cognitively normal and mildly impaired older adults
    Guerry M Peavy
    UCSD Shiley Marcos Alzheimer s Disease Research Center, University of California San Diego, 8950 Villa La Jolla Drive, La Jolla, CA 92037, USA
    Am J Psychiatry 166:1384-91. 2009
    ..The authors sought to determine the prospective association between subjective and objective measures of chronic stress and rate of memory decline in cognitively normal and mildly impaired older adults...
  35. ncbi Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease
    Douglas Galasko
    Department of Neurosciences, University of California at San Diego, San Diego, California, USA
    J Am Geriatr Soc 52:1070-6. 2004
    ..To examine the effect of galantamine on activities of daily living (ADLs) with respect to baseline dementia severity, correlation with cognitive and global function, specific ADLs affected, and maintenance of ADL independence...
  36. pmc Reduced hypocretin (orexin) levels in dementia with Lewy bodies
    STEPHANIE LESSIG
    Departments of Neurosciences, University of California, San Diego, La Jolla, California, USA
    Neuroreport 21:756-60. 2010
    ..These results suggest the involvement of hypocretin in sleep disorders in dementia with Lewy bodies...
  37. ncbi Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease
    Gilbert J Ho
    Department of Neuroscience, University of California, San Diego, La Jolla, CA 92093 0624, USA
    Neuroreport 13:1825-8. 2002
    ..Taken together, these results suggest that for both LBV and AD, earlier age at onset may predict a more aggressive disease course...
  38. ncbi Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease
    Eric Granholm
    VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    Int J Psychophysiol 47:95-115. 2003
    ..The pupillary light reflex test, therefore, may index central cholinergic dysfunction associated with disease progression and improvement in cholinergic function associated with pharmacologic treatment response in AD...
  39. ncbi A comparison of episodic memory deficits in neuropathologically-confirmed Dementia with Lewy bodies and Alzheimer's disease
    Joanne M Hamilton
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093 0948, USA
    J Int Neuropsychol Soc 10:689-97. 2004
    ..These results indicate that while both DLB and AD patients exhibit significant memory impairment, the ability to consolidate information may be less severely impaired in DLB patients than in AD patients...
  40. pmc Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease
    R E Davis
    MitoKor, 11494 Sorrento Valley Road, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 94:4526-31. 1997
    ..We suggest that specific point mutations in the CO1 and CO2 genes cause the CO defect in AD. A CO defect may represent a primary etiologic event, directly participating in a cascade of events that results in AD...
  41. ncbi Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function
    B Teter
    Veterans Administration Greater Los Angeles Healthcare System and Department of Medicine, University of California, Los Angeles, Sepulveda, California 91343, USA
    J Neurosci Res 68:331-6. 2002
    ..These results may have important pharmacogenomic implications for AD therapies that modulate apoE expression levels...
  42. pmc Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins
    Emiley Pham
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093 0624, USA
    FEBS J 277:3051-67. 2010
    ..In conclusion, this study suggests that the presence of a subpopulation of amyloid-beta oligomers in the brains of patients with Alzheimer's disease might be related to alterations in selected synaptic proteins and cognitive impairment...
  43. ncbi Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. HIV Neurobehavioral Research Center Group (HNRC)
    R J Ellis
    Department of Neurosciences, University of California, San Diego, USA
    Neurosci Lett 254:1-4. 1998
    ..251 +/- 185; P = 23). In summary, CSF tau levels were not elevated in patients with HIV-associated neurologic disease...
  44. ncbi DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers
    C F Lippa
    Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19102, USA
    Neurology 68:812-9. 2007
    ....
  45. ncbi Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years
    Chris C Plato
    Department of Neurosciences, University of California San Diego School of Medicine, La Jolla 92093 0624, USA
    Am J Epidemiol 157:149-57. 2003
    ..The rapid decrease in incidence is not likely to be due to genetic factors. Instead, it is most likely to be the results of radical socioeconomic, ethnographic, and ecologic changes brought about by the rapid westernization of Guam...
  46. pmc Brain structure and cerebrovascular risk in cognitively impaired patients: Shanghai Community Brain Health Initiative-pilot phase
    Jing He
    Department of Neurology, University of California at Davis, Sacramento, CA 95817, USA
    Arch Neurol 67:1231-7. 2010
    ....
  47. ncbi Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease
    E Rockenstein
    Department of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA 92093 0624, USA
    Brain Res 914:48-56. 2001
    ..This study suggests that a critical balance among products of the synuclein gene is important to maintain normal brain function and that alterations in this balance might be associated with neurodegenerative disorders...
  48. ncbi Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions
    Katya Rascovsky
    Memory and Aging Center, University of California, San Francisco, CA 94117, USA
    Alzheimer Dis Assoc Disord 21:S14-8. 2007
    ..In this article, we discuss the limitations of current diagnostic criteria and propose the establishment of an international consortium to revise diagnostic and research criteria for the behavioral variant of frontotemporal dementia...
  49. pmc Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels
    Lynn M Bekris
    Geriatric Research, Education, and Clinical Center GRECC, VA Puget Sound Health Care System, Seattle, WA 98108, USA
    J Alzheimers Dis 13:255-66. 2008
    ..Further investigation of the genetic influence of these loci on apoE expression levels in the central nervous system is likely to provide new insight into apoE regulation as well as AD pathogenesis...
  50. ncbi Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
    Sandip Ray
    Satoris, Inc, 2686 Middlefield Road, Suite E, Redwood City, California 94063, USA
    Nat Med 13:1359-62. 2007
    ..Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease...
  51. pmc TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis
    Vivianna M Van Deerlin
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Lancet Neurol 7:409-16. 2008
    ..Our aim was to investigate whether TARDBP is a candidate disease gene for familial ALS that is not associated with mutations in superoxide dismutase 1 (SOD1)...
  52. ncbi Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials
    Michael Grundman
    Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
    Arch Neurol 61:59-66. 2004
    ..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD...
  53. pmc Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy
    Wan Yang
    Department of Pathology, University of Washington, Harborview Medical Center, Box 359791, Seattle, WA 98104, USA
    Am J Pathol 171:993-1002. 2007
    ..These results show that frontal and temporal cortex in PDC is distinguished from AD and PSP by its accumulation of abnormal SNCA and suggest that PDC be considered a synucleinopathy as well as a tauopathy...

Research Grants7

  1. AGE RELATED NEURODEGENERATIVE DISEASES IN MICRONESIA
    Douglas Galasko; Fiscal Year: 2006
    ..Subproject by Lee: 'PHF-tau in neurodegenerative diseases of Guam' will assess oxidative markers related to brain lesions in ALS, PDC and dementia. ..
  2. Biomarkers in Aging, MCI and Alzheimer's Disease
    Douglas Galasko; Fiscal Year: 2007
    ..Banked CSF and plasma will be available for further research into novel biomarkers, including broad-based proteomic studies. ..